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Abstract 
Background & Aims:  There is substantial interest in liquid biopsy approaches for 
cancer early detection, among subjects at risk, using multi-marker panels. CA19-9 is an 
established circulating biomarker for pancreatic cancer. However, its relevance for 
pancreatic cancer early detection or for monitoring subjects at risk has not been 
established.  
Methods:  CA19-9 levels were assessed in blinded sera from 175 subjects collected up 
to 5 years prior to diagnosis of pancreatic cancer and from 875 matched controls from 
the PLCO Cancer Screening Trial. For comparison of performance, CA19-9 was 
assayed in blinded independent sets of samples collected at diagnosis from 129 
subjects with resectable pancreatic cancer and 275 controls (100 healthy subjects; 50 
with chronic pancreatitis; and 125 with non-cancerous pancreatic cysts). The 
complementary value of two additional protein markers, TIMP1 and LRG1, was 
determined.  
Results: In the PLCO cohort, levels of CA19-9 increased exponentially starting at two 
years prior to diagnosis with sensitivities reaching 60% at 99% specificity within 0-6 
months prior to diagnosis for all cases and 50% at 99% specificity for cases diagnosed 
with early-stage disease. Performance was comparable for distinguishing newly 
diagnosed cases with resectable pancreatic cancer from healthy controls (64% 
sensitivity at 99% specificity). Comparison of resectable pancreatic cancer cases to 
subjects with chronic pancreatitis yielded 46% sensitivity at 99% specificity and for 
subjects with non-cancerous cysts 30% sensitivity at 99% specificity. For pre-diagnostic 
cases below cut-off value for CA19-9, the combination with LRG1 and TIMP1 yielded an 
increment of 13.2% in sensitivity at 99% specificity (p=0.031) in identifying cases 
diagnosed within 1 year of blood collection. 
Conclusion: CA19-9 can serve as an anchor marker for pancreatic cancer early 
detection applications.    
Keywords: Biomarker, Detection, Pancreatic Cancer 
Introduction 
Pancreatic ductal adenocarcinoma (PDAC) remains an intractable disease with dismal 
5-year survival rates 1. Poor survival rates are attributed to the fact that most patients
with PDAC present with locally advanced or distant disease (80-85%), with only a
minority of patients initially presenting with surgically resectable disease (15-20%) 2, 3.
Several lines of evidence clearly indicate that survival rates can be improved if PDAC is
identified at early-stage, when the disease is localized and still amenable to surgical
intervention 1, 4-7.
Serum CA19-9 is the main clinically validated tumor marker used in the management of 
PDAC. Concerns regarding CA19-9 have included limited sensitivity for early-stage 
disease8, false-negatives values for subjects that do not produce CA19-9 on account of 
a fucosyltransferase deficiency9, 10 and false-positives values in cases with biliary 
obstruction 11-13. Nevertheless, CA19-9 has proven useful for predicting tumor stage and 
resectability, overall survival, and patient response to therapy 14.  
There is currently substantial interest in liquid biopsy approaches for cancer screening 
whether in a general population setting or for subjects at increased risk. A wide range of 
blood-based biomarkers are currently being investigated including circulating tumor 
DNA (ctDNA) representing mutations or altered methylation patterns; RNA, proteins, 
metabolites, autoantibodies to tumor antigens; exosomes; and circulating tumor cells 15-
20. Performance requirements depend on subjects’ risk, with a need for very high
specificity for subjects at average risk. In the case of pancreatic cancer, risk is
increased based on a personal and family history of cancer, as well as other risk factors
21-26.
CA19-9 has the potential to serve as an anchor marker for pancreatic cancer screening 
that may be complemented with other types of markers. CA19-9 has been reported to 
be elevated in pre-diagnostic PDAC cases among women recruited to the UKCTOCS 
cohort 27. The cohort consisted of post-menopausal women with limited information 
regarding tumor stage at the time of diagnosis 27. In another study, CA19-9 was found to 
be elevated in pre-diagnostic PDAC cases among participants recruited to the 
European EPIC cohort 28. In this cohort, most cases presented with advanced stage 
disease which did not allow assessment of CA19-9 for identifying resectable tumors. In 
a third study, performance of CA19-9 in the pre-diagnostic setting when multiplexed with 
66 additional potential markers was more modest, which may possibly be attributable to 
assay format 29.  
In this study, based on a single-plex ELISA assay to reduce non-specific reactivity, we 
assessed the lead-time trajectory of CA19-9 using blinded pre-diagnostic sera from 175 
PDAC cases and 875 matched cancer-free controls from the PLCO cohort. Similarities 
and differences in performance in the pre-diagnostic vs diagnostic settings were 
assessed using samples from newly diagnosed subjects with resectable disease. 
Samples from subjects presenting with chronic pancreatitis (CP) or cystic lesion(s) of 
the pancreas and from healthy subjects were used as controls. We additionally 
evaluated the potential of two additional previously validated protein markers LRG1 and 
TIMP1 using samples from newly diagnosed subjects with early-stage disease18, for 
their complementary performance with CA19-9 in the pre-diagnostic setting.   
Methods 
PLCO Cohort 
The PLCO Cancer Screening Trial is a randomized multicenter trial in the United States 
which aimed to evaluate the impact of early detection procedures for prostate, lung, 
colorectal and ovarian cancer on disease-specific mortality. Detailed information 
regarding the PLCO cohort is provided elsewhere 30. All subjects involved in this study 
were enrolled with written consent as a criterion for eligibility to participate in the PLCO 
trial. Study recruitment and randomization began November 1993 and was completed in 
July 2001. PLCO eligibility criteria excluded subjects with a previous personal history of 
PLCO cancers, ongoing cancer treatment (excluding basal-cell and squamous-cell skin 
cancer), participation in another cancer screening or cancer primary prevention trial, 
and a recent screening test for prostate or colorectal cancer. The cohort comprises 
approximately 155,000 men and women aged 55 to 74 years old at baseline entry. 
Study participants completed a baseline questionnaire at study entry that includes 
demographic, personal, and medical information including diabetes status. 
Pancreatic cancer cases were identified by self-report in annual mail-in surveys, state 
cancer registries, death certificates, physician referrals and reports from next of kin for 
deceased individuals. All medical and pathologic records related to pancreatic cancer 
diagnosis and supporting documentation were obtained and confirmed by PLCO staff.  
Herein, we analyzed sera from 175 pancreatic cancer cases from the PLCO cohort that 
were diagnosed within 5 years of blood draw and 875 matched controls (Table 1 ). 
Pancreatic cancers were classified as localized, regional, distant, or un-staged using the 
National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) historic 
staging system. Localized disease indicates confinement of the tumor to the pancreas, 
regional disease indicates a tumor that has involved the regional lymph nodes with or 
without direct extension into the surrounding organs or tissues, distant refers to a tumor 
that has spread to part of the body remote from the primary tumor, and un-staged 
indicates that there was insufficient information in the medical records to stage the 
tumor.  Controls, alive at the time when the index case was diagnosed, were matched to 
cases at a ratio of 5∶1 (control:case) based on the distribution of age, race, sex, and 
calendar date of blood draw in 2-month blocks within the case cohort. 
Newly diagnosed pancreatic cancer cohorts 
To compare classifier performance of CA19-9 in the pre-diagnostic and diagnostic 
settings and assess its performance for distinguishing pancreatic cancer from patients 
presenting with chronic pancreatitis (CP) or non-cancerous cystic lesions that were not 
represented in the PLCO cohort, we evaluated plasma samples with two test sets. Test 
Set #1 consisted of 99 patients with early-stage, resected pancreatic adenocarcinoma, 
100 healthy controls, and 50 patients with CP. Patient characteristics are provided in 
Table S5. Pancreatic cancer patients provided informed written consent to collection of 
pre-treatment plasma samples and clinical data abstraction. PDAC patients were 
recruited from cancer clinics at Dana-Farber Cancer Institute/Brigham and Women’s 
Hospital (DFCI/BWH; N=69), Beth Israel Deaconess Medical Center (BIDMC; N=15), 
and Columbia University Irving Medical Center (CUMC; N=15). Healthy control patients 
were recruited from DFCI/BWH (N=94) and CUMC (N=6). Healthy controls were 
undergoing screening colonoscopy (N=91) or accompanying a non-blood related 
relative to an appointment at a gastrointestinal cancer clinic (N=9). Healthy controls had 
no history of cancer in the 5 years prior to sample collection. Pancreatic cancer patients 
and healthy controls were matched on gender and age at the time of blood collection. 
Fifty chronic pancreatitis patients were recruited from gastroenterology clinics at 
DFCI/BWH (N=30), BIDMC (N=15), and CUMC (N=5). Patients were included if clinic 
notes from a gastroenterologist indicated a diagnosis of CP. Pancreatic cancer and CP 
patients were not gender or age matched. Clinical data abstraction was performed 
identically across the sites, with data uploaded to a password-protected REDCap 
database. All plasma samples were collected and processed according to a uniform, 
standardized protocol across the sites and patient groups. 
Test set #2 consisted of 125 patients with low dysplastic grade pancreatic cyst and 30 
patients with resectable pancreatic cancer (8 PDAC and 22 intraductal papillary 
mucinous neoplasms (IPMNs) with an associated invasive ductal adenocarcinoma) from 
the Indiana University School of Medicine. Patient characteristics are provided in Table 
S6. All patients underwent surgical resection of their cystic lesion, and plasma samples 
were collected prior to surgery. Dysplastic grade was histopathology confirmed after 
surgical resection and determined according to WHO criteria. 
Enzyme-linked Immunosorbent Assays 
Plasma protein concentrations for CA19-9, LRG1 and TIMP1 were determined by bead-
based ELISA assays using Luminex multiplexed assay technology ((CA19-9) HCCBP1-
58MAG, (LRG1) HCVD6MAG-67K, (TIMP1) HTMP1MAG-54K, Millipore) as previously 
described 18, 31. We note that the assays for CA19-9, LRG1 and TIMP1 described herein 
are for intended research use only and are not for diagnostic applications. For all ELISA 
experiments, each sample was assayed in singlet and the absorbance or 
chemiluminescence measured with a SpectraMax M5 microplate reader (Molecular 
Devices, Sunnyvale, CA). Samples were analyzed in a blinded fashion, ratio of 
case:control was equilibrated across each analytical plate to mitigate potential bias. An 
internal control sample was run in every plate and each value of the samples was 
divided by the mean value of the internal control in the same plate to correct for 
interpolate variability. Biomarker scores for the 3-marker panel of LRG1, TIMP1 and 
CA19-9 were derived using fixed β-coefficients from a previously developed logistic 
regression model  18. Coefficient of variation (CV) values for CA19-9, LRG1 and TIMP1 
in pooled quality control samples were 11.0, 8.0 and 9.7, respectively.  
 
Statistical Analyses 
Model discrimination was assessed by receiver operating characteristic curve (ROC). 
Time-dependent ROC analyses were performed using pROC (version 1.15.3) in the R 
software environment (version 3.6.1, The R Foundation, https://www.r-project.org). The 
95% confidence intervals (CI) for AUCs were estimated using Delong method 32. A 
fourth order fitted spline curve was used to fit the trajectory of the AUC and sensitivity at 
99% specificity for CA19-9 performance in relation to time to diagnosis from baseline 
blood draw. For these analyses, we considered cases relative to matched controls. 
Specificities at 95% and 99% sensitivities as well as sensitivities at 95% and 99% 
specificities were determined from ROC curves. The 95% CI of sensitivities and 
specificities at specific cut-offs were calculated based on the Exact binomial confidence 
limits, using epi.tests function from epiR (version 1.0.15). P values are reported based 
on 2-sided Wilcoxon rank sum test unless otherwise specified. 
In order to determine the 1-year risk of PDAC and discrimination estimates that reflect 
the background population of the entire PLCO study, we used the case-control 
approach of Schlesselman 1982 33. Briefly, risk scores based on continuous CA19-9 
values were calculated based on a logistic regression model 34. Samples assayed for 
CA19-9 herein reflect a nested case-control cohort that enriches for cases and, 
therefore, do not reflect the true risk of PDAC in the general population. Thus, to 
calculate the estimated absolute risk value based on continuous values of CA19-9 that 
reflect the true risk of PDAC in the entire PLCO population, we used the following 
formula to calculate absolute risk: 
 =  exp (′ +   × 19.9 
)
1 +  exp (′ +   × 19.9 )
 
where  
′ =   − log ! "#$%$1 − "#$%$& +  log '
"()*+,$%-).1 − "()*+,$%-)./ 
In this equation,  is the intercept derived from logistic regression in the nested case 
control cohort, "#$%$ is the prevalence of the disease in our case-enriched dataset "012(3|5#$%$ = 1) and "()*+,$%-). is the prevalence of the disease in the general 
population "012(3|5()*+,$%-). = 1). Quartiles were determined based on CA19-9 
measurements in cases and controls to provide a comparison of the estimated 1-year 
risk for an individual with a CA19-9 value in the first quartile and an individual with a 
CA19-9 value in the fourth quartile. 
The CA19-9 cut-off for the 99% specificity population (CA19-9 > 97.385 U/mL) was 
defined as the threshold value using the measurements of CA19-9 in the one-year 
PLCO population. Emphasis was placed on 99% specificity given the low prevalence of 
PDAC and the need to mitigate false-positives. Confusion matrices were utilized to 
describe the classification model of the 3-marker panel or CA19-9 alone at a >99% 
specificity cutoff. Rows of the matrix display the predicted classes (case or control) 
whereas columns represent the actual classes (case or control). To test whether 3-
marker panel yielded statistically significant classifier improvement over CA19-9, the 
McNemar exact test was applied to the 2x2 contingency table wherein the first cell 
represents the number of patients that both markers predict correctly (a), second one 
represents the number of patients correctly identified by CA19-9 and misclassified by 3-
marker panel (b), third one represents the number of patients misclassified by CA19-9 
but correctly identified by 3-marker panel (c) and the last cell represents the number of 
patients misclassified by both markers (d). Therefore, the null and alternative 
hypothesize are as follows: H ∶ P8 =  P9 H: ∶ P8 <  P9 
Herein, P< denotes the probability of occurrence in cell i. Exact binomial test was used to 
achieve p-value 35. 
 
Figures were generated using GraphPad Prism Version 8.0.0 (GraphPad Software, Inc).  
Results 
CA19-9 performance trajectory in the pre-diagnostic setting  
Testing of CA19-9 was performed using blinded pre-diagnostic sera from 175 
pancreatic cancer cases and 875 matched cancer-free controls from the PLCO cohort. 
Among the 175 pancreatic cancer cases, 62 were diagnosed within the first year and 33 
were diagnosed one to two years after blood collection. The remainder were diagnosed 
2-5 years after blood collection. Controls were matched based on age, sex and race 
(Table 1 ).  
When considering all cases compared to all controls, CA19-9 yielded an Area Under the 
Receiver Operating Characteristic Curve (AUC) of 0.68 (95% CI: 0.64-0.73) with 16.6% 
sensitivity at 99% specificity. Whereas CA19-9 exhibited marginal performance two to 
five years prior to diagnosis, an exponential rise in the classifier performance of CA19-9 
was revealed beginning at 2 years prior to diagnosis with an AUC of 0.77 (95% CI: 0.69-
0.86) 1-2 years prior to diagnosis reaching an AUC of 0.87 (95% CI: 0.78-0.96) when 
considering those cases diagnosed within 0-6M of baseline blood draw (Figure 1 and 
Table S1 ). Corresponding sensitivities of CA19-9 at 99% specificity for 6M-12M, and 0-
6M prior to diagnosis were 24.3%, and 60%, respectively (Figure 1B and Tables S1, 
S2).  
 
The one-year PDAC cancer risk estimates for each study participant according to their 
CA19-9 values adjusted for prevalence of disease based on the entire intervention arm 
of the PLCO population 30 are shown in Figure 2 . We estimated 1-year risks at 0.013% 
and 0.049% assuming CA19.9 value equals to the first and fourth quartile, respectively. 
The 25% percentile, median and 75% percentile one-year risk estimates for participants 
who later diagnosed with PDAC were 0.02%, 0.10% and 0.62%, respectively; these 
values were considerably lower for controls where we have 0.01%, 0.02% and 0.04%, 
respectively. 
 
Of the 175 pancreatic cancer cases in the PLCO cohort, 35 had localized disease, 33 
had regional disease and 92 had distant metastases at the time of clinical diagnosis 
(Table 1 ). CA19-9 performance for distinguishing cases presenting with localized 
disease 1-2 years, 0-1 year and 0-6 months prior to diagnosis from time-interval 
matched controls yielded sensitivities of 12.5%, 15.4% and 50% at 99% specificity 
(Figure 3; Table S3, S4 ). When considering cases presenting with regional disease, 
CA19-9 yielded sensitivity at 99% specificity for cases 1-2 years, 0-1 year and 0-6M 
prior to diagnosis of 0%, 27.3% and 50%, respectively (Figure 3; Table S3, S4 ). 
Resultant sensitivity at 99% specificity of CA19-9 for distinguishing cases presenting 
with distant disease 1-2 years, 0-1 year and 0-6M prior to diagnosis compared to time-
interval matched controls were 10.5%, 52.9% and 68.8% at 99% specificity, respectively 
(Figure 3, Figure S1, Table S3, S4 ).  
 
Notably, cases presenting with localized disease yielded a mean (+/- StDev) CA19-9 
value of 116.24 +/- 94.62 U/mL 0-6 months prior to diagnosis whereas cases presenting 
with distant disease exhibited a mean (+/- StDev) CA19-9 value of 106.3 +/- 110.8 U/mL 
6-12M prior to diagnosis (Figure S1A-D ). These data indicate a six-month time-interval 
latency to achieve comparable levels of CA19-9 between cases presenting with 
localized disease and those with distant disease, suggesting that rapid disease 
progression may occur during this period.  
CA19-9 classifier performance for newly diagnosed resectable PDAC  
We compared performance of CA19-9 for detection of cases subsequently diagnosed 
with early-stage pancreatic cancer with performance at the time of diagnosis of early-
stage pancreatic cancer. Samples from an independent cohort consisting of 99 subjects 
with resectable pancreatic cancer, 100 matched healthy controls and 50 subjects with 
CP were tested (Test Set #1). Patient characteristics are provided in Table S5 . 
Classifier performance of CA19-9 for distinguishing cases from matched healthy 
controls was 0.90 (95% CI: 0.86-0.94) with 64.7% sensitivity at 99% specificity (Figure 
4A) and 0.86 (95% 0.80-0.92) with 46.5% sensitivity at 99% specificity when 
considering cases compared to controls with CP (Figure 4B ). Notably, the classifier 
performance of CA19-9 for identifying of cases versus healthy subjects as determined in 
Test Set #1 was markedly like the performance of CA19-9 for cases presenting with 
localized disease and that were diagnosed within 0-6M of baseline blood draw in the 
PLCO cohort (AUC= 0.89) (Figure 1A ). These findings reinforce lead-time utility of 
CA19-9 for identification of early-stage pancreatic cancer when the disease is still 
operable. 
We further evaluated classifier performance of CA19-9 for distinguishing pancreatic 
cancer cases from subjects harboring non-cancerous IPMN using in an independent 
cohort of 30 resectable pancreatic cancer cases (8 PDAC and 22 IPMNs with an 
associated invasive ductal adenocarcinoma) and 125 subjects with non-cancerous 
IPMN (Test Set #2) (Table S6 ). Classifier performance of CA19-9 for distinguishing 
cases from subjects harboring non-cancerous cysts was 0.76 (95% CI: 0.66-0.85) with 
30% sensitivity at 99% specificity (Figure 4C ). When stratifying cases according to 
those with adenocarcinoma or invasive IPMN, CA19-9 yielded respective AUCs of 0.85 
(95% CI: 0.73-0.97) and 0.72 (95% CI: 0.61-0.84) with corresponding sensitivity of 
37.5% and 27.3% at 99% specificity compared to controls (Figure 4D-E ). 
Additive performance of LRG1 and TIMP1 for identifying pancreatic cancer cases 
not detected with CA19-9 alone 
Selection of the cutoff point to provide exceptionally high specificity to minimize false-
positive results in attenuated sensitivity and cases that are missed. Further, 
approximately ~10% of PDAC subjects have fucosyltransferase deficiency and therefore 
do not produce CA19-9 9, 10. Thus, additional biomarker(s) are needed to complement 
CA19-9 and improve sensitivity while maintaining high specificity. We previously 
validated two protein markers, LRG1 and TIMP1 for detection of symptomatic PDAC at 
an early-stage. A combination rule of LRG1, TIMP1 and CA19-9 yielded improved 
classifier performance for detection of PDAC compared to CA19-9 alone 18. In the 
PLCO cohort, for cases diagnosed within 1 year of baseline blood draw that were 
‘negative’ for CA19-9 (38 out of 62 subjects) based on a 99% specificity cutoff (CA19-9 
< 97.385 U/mL),  the three marker protein panel, using previously fixed beta-coefficients 
of the logistic regression model18, yielded an additional 13.2% sensitivity at >99% 
specificity, compared to CA19-9 alone in identifying cases diagnosed within one year of 
baseline blood draw (Figure 5A; Table S7 ). A confusion matrix reporting the 
performance of the classification model corresponding to the three-marker panel and 
CA19-9 alone indicates that the three-marker panel correctly identified an additional five 
cases that were missed by CA19-9 alone (1-sided McNemar exact test p: 0.031) when 
allowing for equivalent number of false positives (1) (Figure 5B ).  
Discussion 
Our findings establish the utility of CA19-9 for detecting pancreatic cancer amongst 
asymptomatic individuals. Elevated CA19-9 levels began to manifest as early as 2 years 
prior to clinical diagnosis. Importantly, CA19-9 provided important lead-time for 
detection of resectable disease, when multimodality treatment can lead to improved 
long-term survival 1, 4-6.  
The low incidence of PDAC in the average risk population (~8-12 per 100,000) with a 1-
3% lifetime risk of developing disease 36, 37 makes it challenging to implement screening 
for pancreatic cancer in the general population 36, 37. Screening individuals that are at 
high-risk for pancreatic cancer increases the positive predictive value of the test and 
reduces the absolute number of false-positive tests. To-date, several groups have been 
identified at high-risk of PDAC including subjects with inherited risk 23, 38, individuals with 
mucinous cystic lesions of the pancreas 39, subjects with CP 22 as well as individuals 
older than 50 years of age and presenting with new-onset diabetes 24, 40. To this end, 
our data implies that progression of disease can occur rapidly and that the window of 
opportunity to identify pancreatic cancer when disease is still operable is narrow. 
Consequently, testing of CA19-9 amongst high-risk subjects should be performed 
regularly with testing intervals matching their degree of risk. An initial rise in CA19-9 
could then prompt more intensive follow-up whereas a positive test based on a defined 
threshold would trigger an imaging-based modality such as contrast-enhanced 
pancreas protocol CT or MRI/MRCP.  
We note some limitations to our study. Time-dependent AUCs and sensitivity at 99% 
specificity trajectories of CA19-9 were derived based on the availability of plasma 
samples at varying time points before cancer diagnosis from individual patients. 
Availability of serial samples would allow development of longitudinal algorithms and 
assessment of significance of incremental increases in CA19-9 levels. Sub-analyses 
assessing performance of CA19-9 for identifying diabetic subjects that went on to 
develop pancreatic cancer from diabetic subjects that did not go on to develop 
pancreatic cancer was not possible due to limited sample size. Data on benign 
conditions such as CP, pancreatic cystic lesions or obstructive jaundice were lacking in 
the PLCO cohort hence our reliance on additional sources of samples which yielded 
good performance for CA19-9 in distinguishing cases from individuals presenting with 
CP or subjects harboring mucinous cystic lesions of the pancreas with resultant AUCs 
consistent with estimates determined for cases compared to healthy controls. The 
prevalence of cysts in the general population is reported to be between 2.4 to13.5% and 
increases with age 41-44. IPMNs are the most frequent type of pancreatic cyst 45, 46. A 
recent systematic review and meta-analysis found that the probability of IPMN 
progressing to pancreatic cancer within 10 years is approximately 8% for low-risk IPMN 
and 25% for high-risk IPMN 47. Current consensus guidelines recommend either 
resection of IPMN with high-risk of malignancy or surveillance of IPMN without surgical 
indications 48. However, current radiological and clinical guidelines yield satisfactory 
sensitivity but lack specificity for predicting malignant IPMN with high-grade dysplasia or 
invasive carcinoma, compared with surgical pathology 49, 50. In this regard, a recent 
study demonstrated that only 23% of resected IPMNs contain invasive or high-grade 
histology 51. Thus, clinical management of IPMN patients remains a substantial 
challenge. Consequently, the utility of a screening test that can identify individuals 
harboring mucinous cystic lesions of the pancreas that are at high risk of malignant 
transformation or that actively harbor malignancy is clinically desirable. Our findings 
demonstrate that CA19-9 can serve as a lead marker for distinguishing pancreatic 
cancer from non-cancerous pancreatic cysts. 
To-date, several blood-based tests have been proposed for interception of pancreatic 
cancer and other cancer types 15, 52, 53. CancerSEEK, a multi-analyte panel, has shown 
promise for detection of pancreatic cancer at an early-stage with reported ~72% 
sensitivity at >99% specificity 16. Studies exploring utility of cell-free DNA methylation 
patterns for detection of pancreatic cancer have reported sensitivity of 63% and 83% at 
>99% specificity for stage I and II disease, respectively 53. We note that these studies 
were performed in the diagnostic setting and didn’t consider individuals presenting with 
benign conditions of the pancreas. Moreover, the performance of CancerSEEK and 
cfDNA methylation, based on sensitivity at high specificity, was comparable with that of 
CA19-9 observed in our study, providing a compelling rationale for CA19-9 utility as an 
anchor marker for screening of pancreatic cancer. However, given that ~10% of 
individuals lack the ability to produce CA19-9 54, other markers would have 
complementary benefits as demonstrated for LRG1 and TIMP1 in our study resulting in 
capture of additional cases diagnosed within one year that were missed with CA19-9 
alone.   
In conclusion, our findings demonstrate utility of CA19-9 for screening of pancreatic 
cancer. Inclusion of additional markers as demonstrated for LRG1 and TIMP1 and 
potentially in combination with other marker types 15, 17, 19, 52, 53, would have value for 
identifying cases that do not meet CA19-9 cutoff thresholds.  
  
Figure Legends 
Figure 1. Time-dependent classifier performance of CA19-9 in the PLCO Cohort. 
A) AUC point estimates (95% CI) of CA19-9 for distinguishing cases stratified by time to 
diagnosis from baseline blood draw from matched controls. B) Sensitivity (95% CI) of 
CA19-9 at 99% specificity at various lead times. A 4th order fitted spline curve was used 
to illustrate the trajectory of the classifier performance or sensitivity at 99% specificity of 
CA19-9 in relation to time to diagnosis from baseline blood draw. Tabulated values are 
shown in the table beneath the figures.   
Figure 2. Predicted probability of pancreatic cancer within 1 year according to 
CA19-9 values. The rug plot shows the observed distribution of biomarker scores. The 
vertical broken lines correspond to the quartiles threshold for CA19-9 values amongst 
controls (Q1, Q2, Q3, and Q4). 
Figure 3. Time-dependent classifier performance of CA19-9 for cases stratified 
based on presentation of localized, regional or distant disease at time of 
diagnosis and that were diagnosed within 3 years of baseline blood draw in the 
PLCO Cohort. Sensitivity of CA19-9 at 99% specificity for distinguishing cases stratified 
based on presentation of localized, regional or distant disease at time of diagnosis from 
time-interval matched controls. A 4th order fitted spline curve was used to illustrate the 
trajectory of the sensitivity at 99% specificity of CA19-9 in relation to time to diagnosis 
from baseline blood draw.  
Figure 4. Classifier performance of CA19-9 in Test Set #1 and Test Set #2. A-B) 
AUC (95% CI) and sensitivity (95% CI) at 99% specificity of CA19-9 for distinguishing 
resectable PDAC cases (n=99) from matched healthy controls (n=100) (A) or subjects 
with chronic pancreatitis (n=50) (B). C) AUC (95% CI) and sensitivity at 99% specificity 
of CA19-9 for distinguishing resectable PDAC cases (8 PDAC and 22 IPMN with an 
associated invasive ductal adenocarcinoma) from subjects harboring benign IPMN 
(n=125). D-E) AUC (95% CI) and sensitivity (95% CI) at 99% specificity of CA19-9 for 
distinguishing PDAC (n=8) (D) or Invasive IPMN (n=22) (E) from subjects harboring 
benign IPMN (n=125).  
Figure 5. Classifier performance of a 3-marker panel consisting of LRG1, TIMP1 
and CA19-9 for identifying cases diagnosed within 1 year and that were ‘negative’ 
for CA19-9 alone based on a 99% specificity cutoff. A) Scatter plot illustrating the 
distribution of the 3-marker panel scores (Y-axis) and log10 CA19-9 values (X-axis). 
Broken lines represent >99% specificity cutoffs. The 3-marker panel was derived using 
fixed beta-coefficients from the logistic regression model previously developed 
elsewhere 18. B) Confusion matrix describing the performance of the classification 
model corresponding to the 3-marker panel and CA19-9 alone at >99% specificity. 
Statistical significance was determined by 1-sided McNemar exact test.  
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Table Legends 




Table 1. PLCO Patient Characteristics  
    Case/Control Status 
    Non-Case Case 
    N % N % 
Total 875 100 175 100 
Gender 
Female 365 41.71 73 41.71 
Male 510 58.29 102 58.29 
Age At Randomization 
<= 59 185 21.14 37 21.14 
60-64 210 24 42 24 
65-69 325 37.14 65 37.14 
>= 70 155 17.71 31 17.71 
Race 
White 795 90.86 159 90.86 
Black 30 3.43 6 3.43 
Other 50 5.71 10 5.71 
Cigarette Smoking Status 
Never Smoked Cigarettes 426 48.69 65 37.14 
Current Cigarette Smoker 74 8.46 36 20.57 
Former Cigarette Smoker 375 42.86 74 42.29 
BMI at Baseline (In kg/m2) 
Not Answered 7 0.8 0 0 
0-18.5 8 0.91 3 1.71 
18.5-25 306 34.97 57 32.57 
25-30 368 42.06 72 41.14 
30+ 186 21.26 43 24.57 
Diabetic Status 
Unknown 1 0.11 - - 
Yes 55 6.292 23 13.14 
No 819 96.6 152 86.86 
SEER Staging (cases only) 
Unknown     9 5.14 
Localized     35 20 
Regional     33 18.86 







CA19-9 can serve as an anchor marker for pancreatic cancer early detection. Inclusion 
of additional markers such as LRG1 and TIMP1 may have value for identifying cases 
missed by CA19-9 alone. 
 
What You Need to Know 
BACKGROUND AND CONTEXT: Several lines of evidence clearly indicate that 
survival rates for pancreatic cancer can be improved through identification of disease at 
an earlier stage. Herein, we assessed the lead-time trajectory of CA19-9 for early 
detection of pancreatic cancer using pre-diagnostic sera from the PLCO Cancer 
Screening Cohort. We also evaluated the potential of two additional previously validated 
protein markers, LRG1 and TIMP1, for their complementary performance with CA19-9 
in the pre-diagnostic setting.  
NEW FINDINGS: Levels of CA19-9 increased markedly starting at two years prior to 
diagnosis with sensitivities reaching 50% at 99% specificity within 0-6 months prior to 
diagnosis for cases diagnosed with early-stage disease. For pre-diagnostic cases below 
the cut-off value for CA19-9, we further demonstrate that LRG1 and TIMP1 together are 
capable of complementing CA19-9 to enable identification of additional cases missed by 
CA19-9 alone. 
LIMITATIONS: Lack of serial samples did not allow for development of longitudinal 
algorithms and assessment of significance of incremental increases in CA19-9 levels. 
Limited data on benign conditions such as CP, pancreatic cystic lesions, new onset 
diabetes or obstructive jaundice were lacking in the PLCO pre-diagnostic cohort.  
IMPACT: CA19-9 can serve as an anchor marker for pancreatic cancer early detection 
applications. Inclusion of additional markers such as LRG1 and TIMP1 may have value 
for identifying cases that do not meet the CA19-9 cutoff.  
